AEMD
Aethlon Medical, Inc.2.9400
-0.1100-3.61%
Dec 16, 4:00:01 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q3 '26
Trial pool accelerates Cohort 3
Q&A spotlighted a queued pool of screened participants ready for Cohort 3 in the Australian oncology trial, thanks to Trialfacts and Dedicated, with the third Cohort 2 patient treating by late February and DSMB review targeted for late March—quick decisions expected. Management unpacked SLAMB compatibility: PICC-line catheters slash invasiveness, freeing Hemopurifier from dialysis units for oncology infusions, but flow dynamics and FDA steps loom. India trial? Off the table to avoid distraction. A queue awaits Cohort 3. Tone stayed execution-focused; watch DSMB call and trial pace.
Key Stats
Market Cap
2.24MP/E (TTM)
0.01Basic EPS (TTM)
209.20Dividend Yield
0%Recent Filings
8-K
Stockholders approve share increases
10-Q
Q3 FY2026 results
Aethlon narrowed its Q3 FY2026 operating loss to $2.1M, up 14% y/y from $1.8M yet 27% better YTD at $5.4M versus $7.3M, thanks to payroll cuts post-severance and lower clinical spend after scrapping the India trial; R&D rose to $533K from $240K on Australian oncology progress. Cash burn eased to $1.9M (derived). Cash hit $7.0M after $6.7M from PIPE/warrant deals, no debt. Shares jumped 5x y/y to 823K weighted average, slashing diluted EPS loss to $(2.45) from $(10.05). Equity fuels the runway. But FDA funding shortfalls risk trial delays.
8-K
Q3 results: costs down YTD
Aethlon Medical reported Q3 fiscal 2026 results on February 12, 2026, with operating expenses up 13.6% to $2.06 million quarterly yet down 26.9% to $5.36 million year-to-date versus prior year. Cash stood at $7.0 million. Cohort 2 enrollment advances in the Australian oncology trial; Hemopurifier EV research progresses. Cost controls sustain clinical push.
8-K
Warrants now exercisable
Aethlon Medical amended its December 2025 securities purchase agreement and pre-funded warrants with Armistice Capital on January 22, 2026, scrapping the Nasdaq 5635 shareholder approval requirement. Pre-funded warrants are now immediately exercisable, while common warrants still need approval. This accelerates potential cash inflows for the biotech. Dilution risk rises.
8-K
Aethlon prices $3.3M PIPE, inducement
Aethlon Medical entered a PIPE offering on December 5, 2025, issuing 596,452 shares (or pre-funded warrants) and 1,043,791 warrants at $4.03 each to an institutional investor, expected to close December 8. Paired with a warrant inducement, the holder exercises existing March/September 2025 warrants for 210,555 shares at reduced $4.03 price, receiving new warrants for 368,471 shares. Gross proceeds hit ~$3.3M for working capital; warrants need shareholder approval. Deal locks out variable financings for six months.
IPO
Employees
Sector
Industry
ADGM
Adagio Medical Holdings, Inc
1.18+0.35
ADMT
ADM Tronics Unlimited, Inc.
0.11+0.00
AHCO
AdaptHealth Corp.
10.35+0.08
AIMD
Ainos, Inc.
2.15+0.00
AMIX
Autonomix Medical, Inc.
0.63-0.03
APYX
Apyx Medical Corporation
3.72-0.07
EMED
Electromedical Technologies, In
0.00+0.00
RMSL
RemSleep Holdings, Inc.
0.00+0.00
SENS
Senseonics Holdings, Inc.
6.62-0.17
VMD
Viemed Healthcare, Inc.
7.26-0.11